[8-K] TenX Keane Acquisition Unit Reports Material Event
Citius Oncology, Inc. filed a Form 8-K dated August 12, 2025, reporting that it issued a press release announcing its results of operations for the third quarter of fiscal 2025. The press release is furnished as Exhibit 99.1 and is incorporated by reference into the report.
The company clarifies that the Item 2.02 disclosure (including Exhibit 99.1) is furnished and therefore is not deemed "filed" for purposes of Section 18 of the Exchange Act. Item 9.01 lists Exhibits 99.1 and 104 (cover page interactive data), and the filing is signed by Leonard Mazur, Chairman and Chief Executive Officer.
Citius Oncology, Inc. ha depositato un Form 8-K datato 12 agosto 2025, comunicando di aver diffuso un comunicato stampa con i risultati operativi del terzo trimestre dell'esercizio 2025. Il comunicato è allegato come Exhibit 99.1 ed è richiamato nel rapporto.
L'azienda precisa che la divulgazione ai sensi dell'Item 2.02 (incluso l'Exhibit 99.1) è furnished, pertanto non è considerata "filed" ai fini della Section 18 dello Exchange Act. L'Item 9.01 elenca gli Exhibit 99.1 e 104 (dati interattivi della cover page) e il deposito è firmato da Leonard Mazur, Presidente e Amministratore Delegato.
Citius Oncology, Inc. presentó un Form 8-K con fecha 12 de agosto de 2025, informando que emitió un comunicado de prensa con sus resultados operativos del tercer trimestre del ejercicio 2025. El comunicado se adjunta como Exhibit 99.1 y se incorpora por referencia en el informe.
La compañía aclara que la divulgación en el Item 2.02 (incluido el Exhibit 99.1) está furnished y, por tanto, no se considera "filed" a efectos de la Section 18 del Exchange Act. El Item 9.01 enumera los Exhibits 99.1 y 104 (datos interactivos de la portada) y la presentación está firmada por Leonard Mazur, Presidente y Director Ejecutivo.
Citius Oncology, Inc.는 2025년 8월 12일자 Form 8-K를 제출하여 2025 회계연도 3분기 영업실적에 관한 보도자료를 발표했음을 보고했습니다. 해당 보도자료는 Exhibit 99.1로 첨부되었으며 보고서에 의해 참조되어 포함됩니다.
회사 측은 Item 2.02 공시(및 Exhibit 99.1)가 furnished로 제공된 것이며 따라서 Exchange Act의 Section 18 목적상 "filed"로 간주되지 않는다고 명확히 밝혔습니다. Item 9.01에는 Exhibit 99.1 및 104(표지면 인터랙티브 데이터)가 기재되어 있으며 제출문서에는 회장 겸 최고경영자인 Leonard Mazur의 서명이 포함되어 있습니다.
Citius Oncology, Inc. a déposé un Form 8-K daté du 12 août 2025, indiquant avoir publié un communiqué de presse présentant ses résultats d'exploitation pour le troisième trimestre de l'exercice 2025. Le communiqué est annexé en tant que Exhibit 99.1 et est incorporé par renvoi dans le rapport.
La société précise que la divulgation à l'Item 2.02 (y compris l'Exhibit 99.1) est fournie en tant que furnished et n'est donc pas considérée comme "filed" aux fins de la Section 18 de l'Exchange Act. L'Item 9.01 répertorie les Exhibits 99.1 et 104 (données interactives de la page de garde), et le dépôt est signé par Leonard Mazur, Président et Directeur général.
Citius Oncology, Inc. hat ein Form 8-K vom 12. August 2025 eingereicht und berichtet, dass es eine Pressemitteilung zu den Betriebsergebnissen des dritten Quartals des Geschäftsjahres 2025 herausgegeben hat. Die Pressemitteilung ist als Exhibit 99.1 beigefügt und wird durch Bezugnahme in den Bericht aufgenommen.
Das Unternehmen stellt klar, dass die Offenlegung gemäß Item 2.02 (einschließlich Exhibit 99.1) als furnished erfolgt ist und daher für Zwecke von Section 18 des Exchange Act nicht als "filed" gilt. Item 9.01 listet die Exhibits 99.1 und 104 (interaktive Deckblattdaten) auf, und die Einreichung ist von Leonard Mazur, Chairman und Chief Executive Officer, unterzeichnet.
- Press release furnished: The company furnished a press release announcing third-quarter fiscal 2025 results (Exhibit 99.1).
- Filing completeness: Exhibits are listed (99.1 and 104) and the report is signed by Leonard Mazur, Chairman and CEO, indicating proper execution.
- No financial figures provided: The 8-K does not include any revenue, earnings, or other quantitative results—those details are only in the referenced press release.
- Furnished, not filed: Item 2.02 explicitly states the information is furnished and not "filed" under Section 18, which limits certain liabilities related to the disclosure.
Insights
TL;DR: The 8-K notifies investors that a Q3 fiscal 2025 results press release was issued, but provides no financial figures within the filing.
The filing confirms timely disclosure: a press release announcing third-quarter fiscal 2025 results was furnished as Exhibit 99.1. Because no revenue, earnings, guidance, or metrics are included in the 8-K itself, the filing offers limited direct analytical value until the press release content is reviewed. The furnished-not-filed status reduces Section 18 liability for the disclosed text, a common procedural detail but one that affects legal recourse for reliance on the statement within this filing.
TL;DR: Corporate disclosure procedures appear standard: exhibit included and signed by CEO, but substantive detail is only in the press release.
The 8-K properly lists Exhibit 99.1 and the Inline XBRL cover page (Exhibit 104) and is duly executed by the CEO, indicating procedural compliance. The Item 2.02 reservation that the material is furnished, not filed, is explicit and standard practice. From a governance and compliance standpoint, the report meets filing formalities; however, material assessment requires reviewing the attached press release because the 8-K itself contains no financial metrics or operational detail.
Citius Oncology, Inc. ha depositato un Form 8-K datato 12 agosto 2025, comunicando di aver diffuso un comunicato stampa con i risultati operativi del terzo trimestre dell'esercizio 2025. Il comunicato è allegato come Exhibit 99.1 ed è richiamato nel rapporto.
L'azienda precisa che la divulgazione ai sensi dell'Item 2.02 (incluso l'Exhibit 99.1) è furnished, pertanto non è considerata "filed" ai fini della Section 18 dello Exchange Act. L'Item 9.01 elenca gli Exhibit 99.1 e 104 (dati interattivi della cover page) e il deposito è firmato da Leonard Mazur, Presidente e Amministratore Delegato.
Citius Oncology, Inc. presentó un Form 8-K con fecha 12 de agosto de 2025, informando que emitió un comunicado de prensa con sus resultados operativos del tercer trimestre del ejercicio 2025. El comunicado se adjunta como Exhibit 99.1 y se incorpora por referencia en el informe.
La compañía aclara que la divulgación en el Item 2.02 (incluido el Exhibit 99.1) está furnished y, por tanto, no se considera "filed" a efectos de la Section 18 del Exchange Act. El Item 9.01 enumera los Exhibits 99.1 y 104 (datos interactivos de la portada) y la presentación está firmada por Leonard Mazur, Presidente y Director Ejecutivo.
Citius Oncology, Inc.는 2025년 8월 12일자 Form 8-K를 제출하여 2025 회계연도 3분기 영업실적에 관한 보도자료를 발표했음을 보고했습니다. 해당 보도자료는 Exhibit 99.1로 첨부되었으며 보고서에 의해 참조되어 포함됩니다.
회사 측은 Item 2.02 공시(및 Exhibit 99.1)가 furnished로 제공된 것이며 따라서 Exchange Act의 Section 18 목적상 "filed"로 간주되지 않는다고 명확히 밝혔습니다. Item 9.01에는 Exhibit 99.1 및 104(표지면 인터랙티브 데이터)가 기재되어 있으며 제출문서에는 회장 겸 최고경영자인 Leonard Mazur의 서명이 포함되어 있습니다.
Citius Oncology, Inc. a déposé un Form 8-K daté du 12 août 2025, indiquant avoir publié un communiqué de presse présentant ses résultats d'exploitation pour le troisième trimestre de l'exercice 2025. Le communiqué est annexé en tant que Exhibit 99.1 et est incorporé par renvoi dans le rapport.
La société précise que la divulgation à l'Item 2.02 (y compris l'Exhibit 99.1) est fournie en tant que furnished et n'est donc pas considérée comme "filed" aux fins de la Section 18 de l'Exchange Act. L'Item 9.01 répertorie les Exhibits 99.1 et 104 (données interactives de la page de garde), et le dépôt est signé par Leonard Mazur, Président et Directeur général.
Citius Oncology, Inc. hat ein Form 8-K vom 12. August 2025 eingereicht und berichtet, dass es eine Pressemitteilung zu den Betriebsergebnissen des dritten Quartals des Geschäftsjahres 2025 herausgegeben hat. Die Pressemitteilung ist als Exhibit 99.1 beigefügt und wird durch Bezugnahme in den Bericht aufgenommen.
Das Unternehmen stellt klar, dass die Offenlegung gemäß Item 2.02 (einschließlich Exhibit 99.1) als furnished erfolgt ist und daher für Zwecke von Section 18 des Exchange Act nicht als "filed" gilt. Item 9.01 listet die Exhibits 99.1 und 104 (interaktive Deckblattdaten) auf, und die Einreichung ist von Leonard Mazur, Chairman und Chief Executive Officer, unterzeichnet.
FAQ
What did Citius Oncology (CTOR) disclose in this 8-K?
Is the press release in the 8-K considered "filed" or "furnished"?
Which exhibits are attached to this Form 8-K?
Who signed the Form 8-K for Citius Oncology?
Is Citius Oncology identified as an emerging growth company in this filing?
